Triple inhaler therapy for early lung function decline
Part of Lungs & breathing clinical trials.
This trial tests a triple combination inhaler (anti-inflammatory plus two bronchodilators) to see if it can improve lung function in people who are showing early signs of chronic lung damage. It might help if you are a smoker with breathing symptoms and your test shows slightly reduced lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 40 to 75 years
- Smoked for at least 10 pack-years (e.g., 1 pack a day for 10 years)
- Lung function test shows FEV1/FVC between 0.7 and 0.8, with FEV1 under 80% of normal
- Have at least one respiratory symptom lasting 3 months or more: cough, phlegm, or shortness of breath
- No diagnosis of asthma, COPD, or other active lung disease
- No use of inhaled steroids or long-acting bronchodilators in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if exercise can help smokers or former smokers who have early signs of lung trouble (called PRISm) and may later develop COPD. Participation involves exercise and monitoring to see if it can slow or prevent lung disease.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This trial tests whether using a spacer with your inhaler can lower the risk of serious flare-ups for people over 65 who have COPD or asthma and are already on triple therapy.
Hear when a new Preserved Ratio Impaired Spirometry (PRISM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.